针灸疗法对缓解癌症患者因芳香化酶抑制剂治疗引起的关节炎样疼痛有效

2017-12-17 MedSci MedSci原创

12月7日,美国史上最大规模探讨“针灸是否可缓解癌症患者疼痛”的临床试验在“乳腺癌研讨会(圣安东尼奥市,德克萨斯州)”上公布结果:226名分别来自美国11所不同癌症中心的乳腺癌患者临床数据显示,针灸疗法能显著减少正在进行激素治疗的乳腺癌患者痛感,能间接挽救患者生命,提高乳腺癌生存率。 由于阿片类止痛药物不仅有副作用,而且极易上瘾,美国许多癌症中心都开始提供其他止痛辅助疗法。近90%美国国立癌

12月7日,美国史上最大规模探讨“针灸是否可缓解癌症患者疼痛”的临床试验在“乳腺癌研讨会(圣安东尼奥市,德克萨斯州)”上公布结果:226名分别来自美国11所不同癌症中心的乳腺癌患者临床数据显示,针灸疗法能显著减少正在进行激素治疗的乳腺癌患者痛感,能间接挽救患者生命,提高乳腺癌生存率。

由于阿片类止痛药物不仅有副作用,而且极易上瘾,美国许多癌症中心都开始提供其他止痛辅助疗法。近90%美国国立癌症研究所都建议癌症中心尝试针灸疗法,超过70%癌症中心采纳了研究所的建议,将针灸作为癌症治疗副作用的缓解手段1

怀疑派代表耶鲁大学医学院神经科学家Steven Novella在他的“西医(Science-Based Medicine)”博客中写道,针灸没有科学依据。

澳大利亚墨尔本大学的研究团队曾召集282名关节炎患者参与针灸治疗,团队根据治疗结果称针灸对关节炎止痛无效。

哥伦比亚大学医学中心肿瘤学家Dawn Hershman受够了有关针灸到底有没有效果的争论,他认为事实胜于雄辩。

2010年,她在J Clin Oncol发表了一篇文章,招募了51名接受芳香化酶抑制剂治疗的乳腺癌女性患者,证明针灸是一种有效且耐受性良好的癌症治疗辅助策略。芳香化酶抑制剂(aromatase inhibitors)是一种最常见的乳腺癌治疗药物,该药物可降低雌激素水平,长期服用(5-10年)可降低癌症复发风险。但它会导致关节炎样疼痛,超过半数患者因难以忍受的疼痛而中途放弃服药或不定期服药,以至于影响药效2

今年,Hershman和同事们招募了更多志愿者,226名女性患者被分为3组:一组接受真正的针灸治疗;另一组进行非针灸刺激,针尖只穿透非穴位的皮表;第三组不做处理。

经过为期6周的治疗,志愿者根据感受到的痛觉从0到10打分,结果接受了真正针灸治疗的患者普遍比其他两组患者得分低1个点

这是一个令人刮目相看的结果,甚至比西药“度洛西汀(duloxetine)”的止痛效果更好。同时,感觉到切实改善的患者中,针灸治疗的止痛效果比其他两组至少高2个点,其他两组只有30%的患者评价有所改善,针灸治疗组58%患者称疼痛得到了有效缓解

更重要的是,与度洛西汀相比,针灸让患者感受到了持久的长期疗效。Hershman认为,针灸理应可作为阿片类或度洛西汀等西药治疗的合理替代品。

宾夕法尼亚大学疼痛政策研究主任和《Pain Medicine》主编
Rollin Gallagher对Hershman的这项临床试验表示赞同,他说:“小心求证是正确的科学态度,现在已经有临床证据显示针灸疗法切实有效,本研究为此提供了另一个证据。”

参考文献:

1.Growth of Integrative Medicine at Leading Cancer Centers Between 2009 and 2016: A Systematic Analysis of NCI-Designated Comprehensive Cancer Center Websites.J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52). doi: 10.1093/jncimonographs/lgx0

2.Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer.J Clin Oncol. 2010 Mar 1;28(7):1154-60. doi: 10.1200/JCO.2009.23.4708. 

Greenlee H, Crew KD, Capodice J, Awad D, Buono D, Shi Z, Jeffres A, Wyse S, Whitman W, Trivedi MS, Kalinsky K, Hershman DL.Randomized sham-controlled pilot trial of weekly electro-acupuncture for the prevention of taxane-induced peripheral neuropathy in women with early stage breast cancer. Breast Cancer Res Treat. 2016 Apr;156(3):453-464

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851597, encodeId=9c65185159eac, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed May 23 20:02:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265601, encodeId=eebf126560172, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Dec 19 03:02:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289572, encodeId=f75612895e286, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Dec 19 03:02:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360810, encodeId=48ab136081081, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Dec 19 03:02:00 CST 2017, time=2017-12-19, status=1, ipAttribution=)]
    2018-05-23 jklm09
  2. [GetPortalCommentsPageByObjectIdResponse(id=1851597, encodeId=9c65185159eac, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed May 23 20:02:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265601, encodeId=eebf126560172, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Dec 19 03:02:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289572, encodeId=f75612895e286, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Dec 19 03:02:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360810, encodeId=48ab136081081, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Dec 19 03:02:00 CST 2017, time=2017-12-19, status=1, ipAttribution=)]
    2017-12-19 lmm397
  3. [GetPortalCommentsPageByObjectIdResponse(id=1851597, encodeId=9c65185159eac, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed May 23 20:02:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265601, encodeId=eebf126560172, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Dec 19 03:02:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289572, encodeId=f75612895e286, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Dec 19 03:02:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360810, encodeId=48ab136081081, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Dec 19 03:02:00 CST 2017, time=2017-12-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1851597, encodeId=9c65185159eac, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Wed May 23 20:02:00 CST 2018, time=2018-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265601, encodeId=eebf126560172, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Tue Dec 19 03:02:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289572, encodeId=f75612895e286, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Dec 19 03:02:00 CST 2017, time=2017-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360810, encodeId=48ab136081081, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Dec 19 03:02:00 CST 2017, time=2017-12-19, status=1, ipAttribution=)]

相关资讯

“中医针灸全球风采行”走进24个国家和地区

在世界针灸学会联合会成立30周年之际,由世界针灸学会联合会、中国中医科学院、世界卫生组织联合主办,中国针灸学会 、中国中医科学院针灸研究所承办的世界针灸学术大会暨2017中国针灸学会学术年会于近日在北京开幕。

新华社:美国阿片类止痛药滥用与成瘾危机严重,针灸迎来发展时机

新华社华盛顿11月20日电 莎伦又一次躺在熟悉的床位上,针灸师樊蓥轻、稳、准地在她肩部和颈部的重要穴位扎上了细细的针。莎伦的耳边响起了柔和温馨的轻音乐,她慢慢闭上眼,呼吸均匀,心情平和,享受着45分钟的美好时光。

高树中:一针一穴皆学问 愿做愚者为岐黄

药王孙思邈曾说:“世有愚者,读方三年,便谓天下无病可治;及治病三年,乃知天下无方可用。”山东中医药大学副校长高树中常说:“自己就是这样的‘愚者’:学医第九年,才只对后半句有了自体会。为了老百姓的健康,愿意一直做这样的愚者。”

针灸治疗肩周炎循证临床实践指南

全面检索文献,采纳国内外当前最佳证据,根据专家经验和患者价值观,借用证据质量与推荐强度分级系统(GRADE),结合全国范围专家的共识,制定本针灸临床实践指南,为针灸治疗肩周炎提供可靠证据,确保治疗的安全性和有效性。

美国空军将强制实行针灸治疗,墙内开花墙外香

针灸在我国来说已经是十分普遍也受诊人数最为多的国家,早在三皇五帝期间就已经推广开来。治疗或者理疗上一直被推崇,见效快和副作用低是人们选择针灸的理由。就军队而言,各地武警医院军区医院都有针灸门诊,战士在训练中出现各式各样的意外都会接受针灸治疗。可以说和武术一样,提到针灸就会提到中国。

《肩周炎循证针灸临床实践指南》解读

《肩周炎循证针灸临床实践指南》作为中国针灸学会标准已正式发布出版。本文从指南目的、指南方法学、指南适用疾病范围、具体推荐方案主体等方面进行解读,为针灸临床医生使用该《指南》提供便利。